866-997-4948(US-Canada Toll Free)

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 589 Pages

This report provides comprehensive information on the therapeutic development for Glioblastoma Multiforme (GBM), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glioblastoma Multiforme (GBM) and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Glioblastoma Multiforme (GBM) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Glioblastoma Multiforme (GBM) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Glioblastoma Multiforme (GBM) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
Introduction 7
Glioblastoma Multiforme (GBM) Overview 8
Therapeutics Development 9
Glioblastoma Multiforme (GBM) - Therapeutics under Development by Companies 11
Glioblastoma Multiforme (GBM) - Therapeutics under Investigation by Universities/Institutes 22
Glioblastoma Multiforme (GBM) - Pipeline Products Glance 26
Glioblastoma Multiforme (GBM) - Products under Development by Companies 30
Glioblastoma Multiforme (GBM) - Products under Investigation by Universities/Institutes 40
Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 42
Glioblastoma Multiforme (GBM) - Therapeutics Assessment 148
Drug Profiles 173
Glioblastoma Multiforme (GBM) - Recent Pipeline Updates 442
Glioblastoma Multiforme (GBM) - Dormant Projects 550
Glioblastoma Multiforme (GBM) - Discontinued Products 555
Glioblastoma Multiforme (GBM) - Product Development Milestones 556

Appendix 567

List of Table


Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2014 30
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2014 31
Number of Products under Development by Companies, H1 2014 33
Number of Products under Development by Companies, H1 2014 (Contd..1) 34
Number of Products under Development by Companies, H1 2014 (Contd..2) 35
Number of Products under Development by Companies, H1 2014 (Contd..3) 36
Number of Products under Development by Companies, H1 2014 (Contd..4) 37
Number of Products under Development by Companies, H1 2014 (Contd..5) 38
Number of Products under Development by Companies, H1 2014 (Contd..6) 39
Number of Products under Development by Companies, H1 2014 (Contd..7) 40
Number of Products under Development by Companies, H1 2014 (Contd..8) 41
Number of Products under Development by Companies, H1 2014 (Contd..9) 42
Number of Products under Investigation by Universities/Institutes, H1 2014 44
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 45
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..2) 46
Comparative Analysis by Late Stage Development, H1 2014 47
Comparative Analysis by Clinical Stage Development, H1 2014 48
Comparative Analysis by Early Stage Development, H1 2014 49
Comparative Analysis by Unknown Stage Development, H1 2014 50
Products under Development by Companies, H1 2014 51
Products under Development by Companies, H1 2014 (Contd..1) 52
Products under Development by Companies, H1 2014 (Contd..2) 53
Products under Development by Companies, H1 2014 (Contd..3) 54
Products under Development by Companies, H1 2014 (Contd..4) 55
Products under Development by Companies, H1 2014 (Contd..5) 56
Products under Development by Companies, H1 2014 (Contd..6) 57
Products under Development by Companies, H1 2014 (Contd..7) 58
Products under Development by Companies, H1 2014 (Contd..8) 59
Products under Development by Companies, H1 2014 (Contd..9) 60
Products under Investigation by Universities/Institutes, H1 2014 61
Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 62
Glioblastoma Multiforme (GBM) - Pipeline by Johnson & Johnson, H1 2014 63
Glioblastoma Multiforme (GBM) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 64
Glioblastoma Multiforme (GBM) - Pipeline by Celsion Corporation, H1 2014 65
Glioblastoma Multiforme (GBM) - Pipeline by Amgen Inc., H1 2014 66
Glioblastoma Multiforme (GBM) - Pipeline by Sanofi, H1 2014 67
Glioblastoma Multiforme (GBM) - Pipeline by AstraZeneca PLC, H1 2014 68
Glioblastoma Multiforme (GBM) - Pipeline by Eli Lilly and Company, H1 2014 69
Glioblastoma Multiforme (GBM) - Pipeline by GlaxoSmithKline plc, H1 2014 70
Glioblastoma Multiforme (GBM) - Pipeline by Genentech, Inc., H1 2014 71
Glioblastoma Multiforme (GBM) - Pipeline by Agenus, Inc., H1 2014 72
Glioblastoma Multiforme (GBM) - Pipeline by MedImmune, LLC, H1 2014 73
Glioblastoma Multiforme (GBM) - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 74
Glioblastoma Multiforme (GBM) - Pipeline by Lentigen Corporation, H1 2014 75
Glioblastoma Multiforme (GBM) - Pipeline by Sangamo BioSciences, Inc., H1 2014 76
Glioblastoma Multiforme (GBM) - Pipeline by Plexxikon Inc., H1 2014 77
Glioblastoma Multiforme (GBM) - Pipeline by Celltrion, Inc., H1 2014 78
Glioblastoma Multiforme (GBM) - Pipeline by ZIOPHARM Oncology, Inc., H1 2014 79
Glioblastoma Multiforme (GBM) - Pipeline by Novartis AG, H1 2014 80
Glioblastoma Multiforme (GBM) - Pipeline by Actelion Ltd, H1 2014 81
Glioblastoma Multiforme (GBM) - Pipeline by Astellas Pharma Inc., H1 2014 82
Glioblastoma Multiforme (GBM) - Pipeline by Biocon Limited, H1 2014 83
Glioblastoma Multiforme (GBM) - Pipeline by Les Laboratoires Servier SAS, H1 2014 84
Glioblastoma Multiforme (GBM) - Pipeline by Pfizer Inc., H1 2014 85
Glioblastoma Multiforme (GBM) - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 86
Glioblastoma Multiforme (GBM) - Pipeline by Cell Therapeutics, Inc., H1 2014 87
Glioblastoma Multiforme (GBM) - Pipeline by Exelixis, Inc., H1 2014 88
Glioblastoma Multiforme (GBM) - Pipeline by Aduro BioTech, Inc., H1 2014 89
Glioblastoma Multiforme (GBM) - Pipeline by Celgene Corporation, H1 2014 90
Glioblastoma Multiforme (GBM) - Pipeline by Celldex Therapeutics, Inc., H1 2014 92
Glioblastoma Multiforme (GBM) - Pipeline by ImmunoCellular Therapeutics, Ltd., H1 2014 93
Glioblastoma Multiforme (GBM) - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 94
Glioblastoma Multiforme (GBM) - Pipeline by Basilea Pharmaceutica AG, H1 2014 95
Glioblastoma Multiforme (GBM) - Pipeline by Northwest Biotherapeutics, Inc., H1 2014 96
Glioblastoma Multiforme (GBM) - Pipeline by Novogen Limited, H1 2014 97
Glioblastoma Multiforme (GBM) - Pipeline by Oncothyreon Inc., H1 2014 98
Glioblastoma Multiforme (GBM) - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 99
Glioblastoma Multiforme (GBM) - Pipeline by CytRx Corporation, H1 2014 100
Glioblastoma Multiforme (GBM) - Pipeline by Prana Biotechnology Limited, H1 2014 101
Glioblastoma Multiforme (GBM) - Pipeline by Green Cross Cell Corporation, H1 2014 102
Glioblastoma Multiforme (GBM) - Pipeline by Panacea Biotec Limited, H1 2014 103
Glioblastoma Multiforme (GBM) - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 104
Glioblastoma Multiforme (GBM) - Pipeline by Nanobiotix SA, H1 2014 105
Glioblastoma Multiforme (GBM) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2014 106
Glioblastoma Multiforme (GBM) - Pipeline by Fusion Antibodies Ltd, H1 2014 107
Glioblastoma Multiforme (GBM) - Pipeline by Upsher-Smith Laboratories, Inc., H1 2014 108
Glioblastoma Multiforme (GBM) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2014 109
Glioblastoma Multiforme (GBM) - Pipeline by Nerviano Medical Sciences S.r.l., H1 2014 110
Glioblastoma Multiforme (GBM) - Pipeline by Hutchison MediPharma Limited, H1 2014 111
Glioblastoma Multiforme (GBM) - Pipeline by immatics biotechnologies GmbH, H1 2014 112
Glioblastoma Multiforme (GBM) - Pipeline by Apogenix GmbH, H1 2014 113
Glioblastoma Multiforme (GBM) - Pipeline by EnGeneIC Ltd, H1 2014 114
Glioblastoma Multiforme (GBM) - Pipeline by AGY Therapeutics, Inc., H1 2014 115
Glioblastoma Multiforme (GBM) - Pipeline by GenSpera, Inc., H1 2014 116
Glioblastoma Multiforme (GBM) - Pipeline by Diffusion Pharmaceuticals LLC, H1 2014 117
Glioblastoma Multiforme (GBM) - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2014 118
Glioblastoma Multiforme (GBM) - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2014 119
Glioblastoma Multiforme (GBM) - Pipeline by Stemline Therapeutics, Inc., H1 2014 120
Glioblastoma Multiforme (GBM) - Pipeline by BioCancell Therapeutics, Inc., H1 2014 121
Glioblastoma Multiforme (GBM) - Pipeline by Axelar AB, H1 2014 122
Glioblastoma Multiforme (GBM) - Pipeline by Advenchen Laboratories, LLC, H1 2014 123
Glioblastoma Multiforme (GBM) - Pipeline by VG Life Sciences, Inc., H1 2014 124
Glioblastoma Multiforme (GBM) - Pipeline by Noxxon Pharma AG, H1 2014 125
Glioblastoma Multiforme (GBM) - Pipeline by Immunovaccine, Inc., H1 2014 126
Glioblastoma Multiforme (GBM) - Pipeline by Globeimmune, Inc., H1 2014 127
Glioblastoma Multiforme (GBM) - Pipeline by InteRNA Technologies B.V., H1 2014 128
Glioblastoma Multiforme (GBM) - Pipeline by ChemoCentryx, Inc., H1 2014 129
Glioblastoma Multiforme (GBM) - Pipeline by Xcovery, Inc., H1 2014 130
Glioblastoma Multiforme (GBM) - Pipeline by TVAX Biomedical, Inc., H1 2014 131
Glioblastoma Multiforme (GBM) - Pipeline by Biovista Inc., H1 2014 132
Glioblastoma Multiforme (GBM) - Pipeline by Sirnaomics, Inc., H1 2014 133
Glioblastoma Multiforme (GBM) - Pipeline by CureTech Ltd., H1 2014 134
Glioblastoma Multiforme (GBM) - Pipeline by Oncovir, Inc., H1 2014 135
Glioblastoma Multiforme (GBM) - Pipeline by TRACON Pharmaceuticals, Inc., H1 2014 136
Glioblastoma Multiforme (GBM) - Pipeline by Nexgenix Pharmaceuticals, LLC, H1 2014 137
Glioblastoma Multiforme (GBM) - Pipeline by Regulus Therapeutics Inc., H1 2014 138
Glioblastoma Multiforme (GBM) - Pipeline by Immunomic Therapeutics, Inc., H1 2014 139
Glioblastoma Multiforme (GBM) - Pipeline by CLL Pharma, H1 2014 140
Glioblastoma Multiforme (GBM) - Pipeline by DiscoveryBiomed, Inc., H1 2014 141
Glioblastoma Multiforme (GBM) - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2014 142
Glioblastoma Multiforme (GBM) - Pipeline by GreenPeptide Co., Ltd., H1 2014 143
Glioblastoma Multiforme (GBM) - Pipeline by Incuron, LLC, H1 2014 144
Glioblastoma Multiforme (GBM) - Pipeline by Terpenoid Therapeutics, Inc., H1 2014 145
Glioblastoma Multiforme (GBM) - Pipeline by TAU Therapeutics, LLC, H1 2014 146
Glioblastoma Multiforme (GBM) - Pipeline by EirGen Pharma Ltd., H1 2014 147
Glioblastoma Multiforme (GBM) - Pipeline by CytoVac A/S, H1 2014 148
Glioblastoma Multiforme (GBM) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 149
Glioblastoma Multiforme (GBM) - Pipeline by Selvita S.A, H1 2014 150
Glioblastoma Multiforme (GBM) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 151
Glioblastoma Multiforme (GBM) - Pipeline by Advanced Accelerator Applications, H1 2014 152
Glioblastoma Multiforme (GBM) - Pipeline by EntreChem, S.L., H1 2014 153
Glioblastoma Multiforme (GBM) - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 154
Glioblastoma Multiforme (GBM) - Pipeline by Oligovax SAS, H1 2014 155
Glioblastoma Multiforme (GBM) - Pipeline by Ecrins Therapeutics SAS, H1 2014 156
Glioblastoma Multiforme (GBM) - Pipeline by Sagetis Biotech, S.L., H1 2014 157
Glioblastoma Multiforme (GBM) - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 158
Glioblastoma Multiforme (GBM) - Pipeline by Activartis Biotech GmbH, H1 2014 159
Glioblastoma Multiforme (GBM) - Pipeline by CytomX Therapeutics, Inc., H1 2014 160
Glioblastoma Multiforme (GBM) - Pipeline by Panacela Labs, Inc., H1 2014 161
Glioblastoma Multiforme (GBM) - Pipeline by Bioncotech Therapeutics S.L., H1 2014 162
Glioblastoma Multiforme (GBM) - Pipeline by Antoxis Limited, H1 2014 163
Glioblastoma Multiforme (GBM) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2014 164
Glioblastoma Multiforme (GBM) - Pipeline by AbbVie Inc., H1 2014 165
Glioblastoma Multiforme (GBM) - Pipeline by Argon Pharma S.L., H1 2014 166
Glioblastoma Multiforme (GBM) - Pipeline by AlphaMab Co., Ltd, H1 2014 167
Glioblastoma Multiforme (GBM) - Pipeline by Galileo Research s.r.l., H1 2014 168
Assessment by Monotherapy Products, H1 2014 169
Assessment by Combination Products, H1 2014 170
Number of Products by Stage and Target, H1 2014 173
Number of Products by Stage and Mechanism of Action, H1 2014 182
Number of Products by Stage and Route of Administration, H1 2014 190
Number of Products by Stage and Molecule Type, H1 2014 193
Glioblastoma Multiforme (GBM) Therapeutics - Recent Pipeline Updates, H1 2014 463
Glioblastoma Multiforme (GBM) - Dormant Projects, H1 2014 571
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..1), H1 2014 572
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..2), H1 2014 573
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..3), H1 2014 574
Glioblastoma Multiforme (GBM) - Dormant Projects (Contd..4), H1 2014 575
Glioblastoma Multiforme (GBM) - Discontinued Products, H1 2014 576

List of Chart


Number of Products under Development for Glioblastoma Multiforme (GBM), H1 2014 30
Number of Products under Development for Glioblastoma Multiforme (GBM) - Comparative Analysis, H1 2014 31
Number of Products under Development by Companies, H1 2014 32
Number of Products under Investigation by Universities/Institutes, H1 2014 43
Comparative Analysis by Late Stage Development, H1 2014 47
Comparative Analysis by Clinical Stage Development, H1 2014 48
Comparative Analysis by Early Stage Products, H1 2014 49
Assessment by Monotherapy Products, H1 2014 169
Assessment by Combination Products, H1 2014 170
Number of Products by Top 10 Target, H1 2014 171
Number of Products by Stage and Top 10 Target, H1 2014 172
Number of Products by Top 10 Mechanism of Action, H1 2014 180
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 181
Number of Products by Top 10 Route of Administration, H1 2014 188
Number of Products by Stage and Top 10 Route of Administration, H1 2014 189
Number of Products by Top 10 Molecule Type, H1 2014 191
Number of Products by Stage and Top 10 Molecule Type, H1 2014 192

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *